% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Xie:300252,
      author       = {R. Xie$^*$ and T. Vlaski$^*$ and K. Trares$^*$ and C.
                      Herder and B. Holleczek and H. Brenner$^*$ and B.
                      Schöttker$^*$},
      title        = {{L}arge-{S}cale {P}roteomics {I}mprove {R}isk {P}rediction
                      for {T}ype 2 {D}iabetes.},
      journal      = {Diabetes care},
      volume       = {48},
      number       = {6},
      issn         = {0149-5992},
      address      = {Alexandria, Va.},
      publisher    = {Assoc.},
      reportid     = {DKFZ-2025-00713},
      pages        = {922-926},
      year         = {2025},
      note         = {#EA:C070#LA:C070# / 2025 Jun 1;48(6):922-926},
      abstract     = {This study evaluated the incremental predictive value of
                      proteomic biomarkers in assessing 10-year type 2 diabetes
                      risk when added to the clinical Cambridge Diabetes Risk
                      Score (CDRS).Data from 21,898 UK Biobank participants were
                      used for model derivation and internal validation, and 4,454
                      Epidemiologische Studie zu Chancen der Verhütung,
                      Früherkennung und optimierten Therapie chronischer
                      Erkrankungen in der älteren Bevölkerung (ESTHER) cohort
                      (Germany) participants were used for external validation.
                      Proteomic profiling included the Olink Explore (2,085
                      proteins) and Olink Target 96 Inflammation panel (73
                      proteins).Adding 15 proteins from Olink Explore or 6
                      proteins from the Olink Inflammation panel improved the
                      C-index of the CDRS by 0.029 or 0.016 in internal validation
                      with net reclassification of $23.0\%$ and $29.0\%,$
                      respectively. External validation was only conducted for the
                      six-protein-extended model, and the C-index improved by
                      0.014.The Olink Explore-based 15-protein model enhanced the
                      CDRS model performance most, and this promising prediction
                      model should be externally validated. Our successful
                      external validation of the Olink Inflammation panel-based
                      six-protein model shows that this is a promising endeavor.},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40178901},
      doi          = {10.2337/dc24-2478},
      url          = {https://inrepo02.dkfz.de/record/300252},
}